💊
Livmarli
maralixibat chloride
Sindromul Alagille
✅ Autorizat
✅
Nu există alerte active
Acest medicament nu are penurii în curs, scrisori de siguranță sau retrageri de pe piață.
La ce se utilizează
Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older, Progressive familial intrahepatic cholestasis (PFIC) in patients 3 months of age and older. Livmarli tablets is indicated in adults and adolescents 12 years and older for the treatment of: Cholestatic pruritus in patients with Alagille syndrome (ALGS), Progressive familial intrahepatic cholestasis (PFIC).
⚠️ Siguranță a pacientului
No
Pagina oficială EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli